Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Press Release".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences reported strong Q4FY26 results with revenue of Rs. 75,870 million, up 16% YoY, and EBITDA of Rs. 25,544 million, up 20% YoY with margin improvement of 110 basis points to 33.7%. For the full year FY26, revenue grew 17% to Rs. 271,484 million with EBITDA up 20% to Rs. 84,751 million. Net profit (adjusted) for FY26 stood at Rs. 54,564 million, up 15% YoY. The Board recommended 100% dividend and approved a share buyback of up to Rs. 11,000 million at Rs. 1,150 per share (16% premium). Key business highlights include India Formulations growing 14%, International Markets up 45%, Consumer Wellness surging 61%, while North America Formulations declined 6%. The company also announced acquisition of US-based Assertio Holdings for US$ 166 million to strengthen its specialty portfolio.
Strong operational performance with margin expansion and shareholder-friendly actions (dividend + buyback) signal management confidence. The Rs. 11,000 million buyback at 16% premium provides near-term price support, while the Assertio acquisition should strengthen the US specialty business. Net Debt to Equity of 0.16x indicates a healthy balance sheet for further investments.